More supply for AtCor
Wednesday, 08 October, 2008
AtCor Medical [ASX: ACG] has signed an agreement to supply its SphygmoCor systems and clinical trial support services to an international pharmaceutical company.
The contract is worth at least US$930,000 [AUD$1.3 million], and has brought to US$3.7 million [AUD$5.2 million] the total value of pharmaceutical trial contracts secured by AtCor in the past 130 days.
SphygmoCor visibly identifies the effects of reflected blood pressure in the central aortic wave. This measure can't be detected with standard blood pressure monitoring.
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
Existing medicines could help treat deadly childhood dementia
Australian researchers have identified several existing TGA‑approved medicines that could help...
